Susquehanna Fundamental Investments LLC Purchases New Shares in CVS Health Co. (NYSE:CVS)

Susquehanna Fundamental Investments LLC purchased a new position in CVS Health Co. (NYSE:CVS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 628,540 shares of the pharmacy operator's stock, valued at approximately $28,215,000.

Other hedge funds also recently modified their holdings of the company. Principal Financial Group Inc. increased its position in shares of CVS Health by 4.8% in the third quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator's stock worth $90,200,000 after purchasing an additional 66,244 shares during the period. Hall Laurie J Trustee increased its position in shares of CVS Health by 25,484.4% in the fourth quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator's stock worth $517,000 after purchasing an additional 11,468 shares during the period. B&D White Capital Company LLC bought a new position in shares of CVS Health in the fourth quarter worth $417,000. Watts Gwilliam & Co. LLC grew its position in CVS Health by 9.8% in the fourth quarter. Watts Gwilliam & Co. LLC now owns 7,302 shares of the pharmacy operator's stock valued at $334,000 after acquiring an additional 650 shares during the last quarter. Finally, Seizert Capital Partners LLC grew its position in CVS Health by 22.8% in the fourth quarter. Seizert Capital Partners LLC now owns 569,527 shares of the pharmacy operator's stock valued at $25,566,000 after acquiring an additional 105,708 shares during the last quarter. Institutional investors own 80.66% of the company's stock.

Insiders Place Their Bets

In other CVS Health news, Director Michael F. Mahoney acquired 30,000 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now owns 39,356 shares of the company's stock, valued at approximately $2,625,045.20. This represents a 320.65 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP James David Clark sold 7,513 shares of the firm's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.22% of the company's stock.

Wall Street Analyst Weigh In

CVS has been the topic of a number of recent analyst reports. Mizuho lifted their target price on CVS Health from $70.00 to $76.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Robert W. Baird lifted their target price on CVS Health from $51.00 to $71.00 and gave the company a "neutral" rating in a research report on Tuesday, April 15th. Morgan Stanley reiterated an "overweight" rating on shares of CVS Health in a research report on Tuesday, April 15th. Evercore ISI lifted their target price on CVS Health from $60.00 to $65.00 and gave the company an "outperform" rating in a research report on Monday, January 27th. Finally, Piper Sandler lifted their price target on CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a research note on Friday, March 21st. Four equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, CVS Health currently has an average rating of "Moderate Buy" and an average price target of $71.83.

CVS Health Trading Up 0.1 %

Shares of CVS traded up $0.07 during trading hours on Tuesday, hitting $65.00. 9,300,849 shares of the stock were exchanged, compared to its average volume of 11,836,170. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $71.45. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.81 and a quick ratio of 0.60. The business has a 50-day moving average of $66.45 and a 200-day moving average of $58.75. The firm has a market capitalization of $81.95 billion, a P/E ratio of 17.76, a price-to-earnings-growth ratio of 0.98 and a beta of 0.57.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. On average, research analysts expect that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Tuesday, April 22nd will be issued a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 4.09%. The ex-dividend date is Tuesday, April 22nd. CVS Health's payout ratio is 72.68%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.